POST Online Media Lite Edition



 

Teva Pharma completes Actavis Generics acquisition

Staff Writer |
Teva Pharmaceutical Industries announced that its has completed its acquisition of Allergan’s generics business Actavis Generics.

Article continues below






With the acquisition, Teva now has approximately 338 product registrations pending FDA approval and holds the leading position in first-to-file opportunities with approximately 115 pending ANDAs in the U.S.

In Europe, after divestitures; Teva will have a pipeline capable of over 5000 launches across the region.

In Teva growth markets including, Asia, Africa, Latin America, Middle East, Russia and CIS, there are now approximately 600 pending product approvals. Overall, Teva is planning for 1,500 generic launches globally in 2017.

Teva’s products generated approximately $215 billion in savings in the last decade to the U.S. healthcare system; this number will continue to increase and even accelerate as a result of the acquisition.


What to read next

Teva completes £603 million sale of UK and Ireland Actavis assets
Sagent Pharma to buy ANDA Portfolio from Teva Pharma in $40m deal
Teva withdraws from Mylan, will buy Allergan Generics in $40.5 billion transaction